CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy: Further, the 2021 EFNS/PNS guidelines suggest considering testing for nodal and paranodal antibodies in all the patients with clinical suspicion of CIDP when nodal and paranodal (anti-NF155, anti-CNTN1, anti-Caspr1) and possibly anti-NF140/186 antibody testing is available and meeting quality standards.